Their profiles can be assigned to a GCIMP module hypermethylated in IDH-mut tumors (spot D’); a GCIMP-O module with specifically enhanced methylation in IDH-O; a module hypermethylated specifically in IDH-wt gliomas and IDH-O (GCIMP-wt, spot F’); and an ‘anti-GCIMP’ module (A’) hypermethylated in IDH-wt and hypomethylated in IDH-mut that resemble the RTKII and the mesenchymal methylation signatures in GBM, respectively [9,20,29]. The gene discussed is IDH1; the disease is central nervous system cancer.